Peptides in Skincare: How They Work and Why They Matter

Key Takeaways

• Compounds covered: Signal peptides (pal-KTTKS/Matrixyl), neurotransmitter-inhibitor peptides (argireline/acetyl hexapeptide-3), carrier peptides (GHK-Cu), enzyme-inhibitor peptides, acetyl tripeptide-30 citrulline
• Goal area: Skin collagen support, wrinkle reduction, barrier function, skin hydration
• Evidence range: Ranges from randomized controlled trials (pal-KTTKS, argireline) to in vitro and ex vivo data (newer signal peptide analogs); topical cosmetic evidence is generally limited to cosmeceutical-grade trials rather than pharmaceutical-level RCTs
• Regulatory range: Topical peptides are regulated as cosmetic ingredients under FDA cosmetics law; injectable GHK-Cu is not FDA-approved and is available through compounding
• Key biomarkers for injectable peptide use: IGF-1, comprehensive metabolic panel (ALT, AST, eGFR), CBC
• As of April 2026: Topical cosmetic peptides (pal-KTTKS, argireline, GHK-Cu) are regulated as cosmetic ingredients and are outside the scope of FDA actions that have restricted compounding access to certain injectable peptides (including BPC-157 and TB-500) in early 2026. Injectable GHK-Cu is not FDA-approved for any indication; lawful availability through Section 503A compounding depends on its current status on FDA's 503A bulk drug substances list, which is subject to ongoing FDA rulemaking.
• Bottom line: Topical peptides with the strongest evidence are pal-KTTKS and argireline; GHK-Cu bridges topical cosmetic and injectable applications with distinct evidence bases for each route.

Understanding Skin Aging: The Biology

Skin aging is not a single event. It is the progressive disruption of a signaling system. The dermal extracellular matrix (ECM) — a network of collagen fibrils, elastin, proteoglycans, and fibronectin — forms the structural architecture of the dermis. Fibroblasts, the primary dermal cell type, both produce this matrix and respond to it. In young skin, intact collagen fibrils maintain mechanical tension on fibroblasts, which in turn signals continued collagen production. This feedback loop sustains dermal integrity.

With age, two converging processes disrupt the loop. Intrinsic aging reduces fibroblast proliferative capacity. Extrinsic aging, particularly UV radiation, elevates matrix metalloproteinase (MMP) activity. Cole and colleagues, in a 2018 review in Journal of Cell Communication and Signaling, reframed skin aging as a failure of fibroblast-ECM interaction driven by collagen fibril fragmentation. When collagen fragments, fibroblasts lose mechanical tension. Without tension, they reduce collagen synthesis, adopt a senescent morphology, and increase MMP output — a positive-feedback cycle that accelerates matrix degradation. Quan and colleagues, in a 2013 study also published in the Journal of Investigative Dermatology, demonstrated elevated MMP activity and collagen fragmentation in photodamaged skin, directly impairing fibroblast function.

This biology is why peptides are mechanistically relevant to skin aging. Each of the four cosmeceutical peptide classes intervenes at a different point in this degradation cycle. Signal peptides re-stimulate fibroblast collagen synthesis. Carrier peptides deliver cofactors required for collagen cross-linking. Neurotransmitter-inhibitor peptides reduce the mechanical repetition that creates expression lines. Enzyme-inhibitor peptides suppress the MMPs that degrade existing matrix. Understanding the class tells you which part of the biology a given ingredient is targeting.

Peptides Studied for Skin: A Quick Comparison

The following peptide classes and representative compounds have published evidence relevant to skin aging and appearance. They are organized by class, then by strength of clinical evidence within each class.

• Compound: Palmitoyl pentapeptide (pal-KTTKS / Matrixyl)
  Mechanism: Signal peptide — matrikine fragment that stimulates fibroblast production of collagen I, III, and fibronectin
  Evidence: 12-week double-blind split-face RCT; significant wrinkle/fine line reduction vs. placebo
  FDA status: Regulated as cosmetic ingredient; not evaluated or approved as a drug
  SP availability: Available as a topical cosmetic ingredient (not through Superpower)
  Route: Topical
• Compound: Argireline (acetyl hexapeptide-3)
  Mechanism: Neurotransmitter-inhibitor — SNARE complex partial inhibitor reducing repetitive facial muscle contraction
  Evidence: Randomized placebo-controlled trial; 48.9% reduction on the study's composite anti-wrinkle measure versus 0% for placebo on the same measure
  FDA status: Regulated as cosmetic ingredient
  SP availability: Available as a topical cosmetic ingredient (not through Superpower)
  Route: Topical
• Compound: GHK-Cu (copper tripeptide-1) — topical
  Mechanism: Carrier peptide — delivers copper for collagen/elastin synthesis; also modulates wound healing and antioxidant defense
  Evidence: In vitro collagen synthesis stimulation established since 1988; limited topical RCT data; synergy with hyaluronic acid demonstrated in ex vivo models
  FDA status: Topical form regulated as cosmetic ingredient
  SP availability: Available as a topical cosmetic ingredient (not through Superpower)
  Route: Topical
• Compound: GHK-Cu — injectable (compounded)
  Mechanism: Systemic copper peptide with broader gene expression modulation, antioxidant, anti-inflammatory, and tissue repair actions
  Evidence: Preclinical and in vitro; limited clinical data from compounded use; no completed Phase 3 RCT
  FDA status: Not FDA-approved for any indication; lawful § 503A compounding availability depends on the substance's current status on FDA's 503A bulk drug substances list (subject to ongoing FDA rulemaking)
  SP availability: Not available through Superpower
  Route: Subcutaneous injection
• Compound: Acetyl tripeptide-30 citrulline
  Mechanism: Signal peptide — upregulates aquaporin-3 expression to improve transepidermal water regulation
  Evidence: In vitro evidence for aquaporin-3 upregulation; limited clinical data
  FDA status: Regulated as cosmetic ingredient
  SP availability: Available as a topical cosmetic ingredient (not through Superpower)
  Route: Topical

Compounds listed above as cosmetic ingredients are regulated under FDA cosmetics law. They are not evaluated or approved to diagnose, treat, cure, or prevent any disease or medical condition. Injectable GHK-Cu is not FDA-approved for any indication; lawful availability through US compounding pharmacies under Section 503A depends on the substance's current status on FDA's 503A bulk drug substances list.

Peptide Classes Used in Skincare: Individual Profiles

Each peptide class targets a distinct mechanism in skin biology. The evidence base and appropriate use context differ substantially between classes. What follows covers each class using the compound with the strongest published evidence as the representative example.

Signal peptides: the matrikine and synthetic signaling class

Signal peptides are among the most clinically studied classes in cosmeceutical skincare. The class includes matrikines — naturally occurring ECM-derived peptide fragments that signal dermal repair — and synthetic analogs designed to mimic those signals. Lintner and Peschard, writing in the International Journal of Cosmetic Science in 2000, established how biologically active peptide fragments can trigger collagen synthesis in skin care applications in fibroblast models, providing the foundational rationale for this entire compound class.

The representative compound is palmitoyl pentapeptide (pal-KTTKS, marketed as Matrixyl). The palmitoyl fatty acid modification enhances skin penetration by increasing lipophilicity. Robinson and colleagues conducted a 12-week double-blind split-face RCT of pal-KTTKS in a moisturizer formulation, published in the International Journal of Cosmetic Science in 2005, demonstrating significant wrinkle and fine line reduction at a concentration of just 3 parts per million. [RCT] The same compound was evaluated for dermal stability and skin permeability by Choi and colleagues in a 2014 study in Biomolecules & Therapeutics, reported that pal-KTTKS penetrates into all skin layers including the dermis in hairless mouse skin, though full transdermal permeation was not detected under study conditions. Human skin permeation data are more limited.

A more recent signal peptide, acetyl tripeptide-30 citrulline, operates through a different mechanism: upregulation of aquaporin-3, a channel protein that facilitates water transport across the cell membrane. Liu and colleagues, publishing in International Journal of Pharmaceutics in 2024, demonstrated increased aquaporin-3 expression and hydration-related biomarker changes in HaCaT cell and mouse models, illustrating how the signal peptide class continues to expand toward new mechanistic targets beyond collagen synthesis. Human clinical outcome data for this specific peptide remain limited. [In vitro and animal study]

A 2019 randomized controlled trial by Maia Campos and colleagues, comparing topical and oral peptide delivery published in Journal of Cosmetic Dermatology, reported improvements in skin viscoelasticity and density with both routes, with topical application producing localized effects. Oral peptide delivery is outside the scope of this article.

Carrier peptides: delivering cofactors to the dermis

Carrier peptides do not primarily signal cells. They deliver trace elements that fibroblasts require to complete collagen and elastin synthesis. The primary commercial example is GHK-Cu (glycine-histidine-lysine complexed with copper), a tripeptide present naturally in human plasma.

Copper is an essential cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibrils. Without adequate copper delivery, newly synthesized collagen chains cannot be properly cross-linked, reducing their structural contribution to the dermis. Maquart and colleagues, in the foundational 1988 study in FEBS Letters, demonstrated that GHK-Cu stimulates collagen synthesis in fibroblast cultures at concentrations as low as 10⁻¹² M. [In vitro]

Pickart and colleagues, reviewing GHK as a natural skin modulator in BioMed Research International in 2015, described GHK-Cu's influence on multiple cellular pathways — including antioxidant gene expression, anti-inflammatory signaling, and wound contraction — that extend well beyond simple cofactor delivery. This breadth of activity is relevant because it distinguishes GHK-Cu from peptides with single, well-characterized mechanisms.

Jiang and colleagues, in a 2023 study in Journal of Cosmetic Dermatology, demonstrated synergy between GHK-Cu and hyaluronic acid for upregulation of collagen IV in fibroblast models and ex vivo skin, suggesting formulation pairing may amplify the copper peptide's ECM-remodeling signals at the cellular level. [In vitro / ex vivo]

Topical GHK-Cu is regulated as a cosmetic ingredient and does not require a prescription. Injectable GHK-Cu is a compounded peptide with a different regulatory status and evidence base, discussed in the bridge section below.

Neurotransmitter-inhibitor peptides: the expression-line class

Neurotransmitter-inhibitor peptides reduce the muscular activity responsible for expression lines. They act at the neuromuscular junction rather than in the dermis, making them mechanistically distinct from signal and carrier peptides.

The primary compound in this class is argireline (acetyl hexapeptide-3). Blanes-Mira and colleagues, in the original 2002 characterization published in the International Journal of Cosmetic Science, described argireline as a synthetic hexapeptide that inhibits SNARE protein complex formation, the molecular complex that governs acetylcholine release at the neuromuscular junction. By partially inhibiting this complex, argireline reduces the frequency and force of facial muscle contractions that create and deepen expression lines. [In vitro / mechanistic characterization]

Wang and colleagues subsequently conducted a randomized placebo-controlled trial of argireline, published in the American Journal of Clinical Dermatology in 2013, demonstrating a 48.9% reduction on the study's composite anti-wrinkle measure versus 0% for placebo on the same measure over the study period. [RCT] The effect is modest by clinical pharmacology standards, and topical application produces substantially milder muscle relaxation than intramuscular botulinum toxin injection. The mechanism is functionally analogous but not equivalent.

Enzyme-inhibitor peptides: protecting existing collagen

Enzyme-inhibitor peptides complement signal peptides by suppressing the matrix metalloproteinases (MMPs) responsible for degrading collagen and elastin. Where signal peptides try to produce new collagen, enzyme-inhibitor peptides try to preserve existing matrix from enzymatic breakdown.

The role of MMP inhibition in skin aging is supported by the photodamage research of Quan and colleagues, whose 2013 Journal of Investigative Dermatology study showed elevated MMP activity is central to accelerated collagen fragmentation in photodamaged skin. MMP inhibition is a mechanistically established target in photodamaged skin, though compound-specific RCTs for enzyme-inhibitor peptides remain limited compared to the signal peptide class.

Regulatory Status at a Glance

As of April 2026, the peptide compounds discussed in this article carry the following regulatory statuses:

• Palmitoyl pentapeptide (pal-KTTKS/Matrixyl): Regulated as a cosmetic ingredient under FDA cosmetics law. Not evaluated or approved as a drug. No prescription required for topical use.
• Argireline (acetyl hexapeptide-3): Regulated as a cosmetic ingredient. Not evaluated or approved as a drug. No prescription required for topical use.
• GHK-Cu (topical): Regulated as a cosmetic ingredient. Not evaluated or approved as a drug. No prescription required for topical use.
• GHK-Cu (injectable/compounded): Not FDA-approved for any indication. Lawful availability through 503A compounding depends on the substance's current status on FDA's 503A bulk drug substances list, which is subject to ongoing FDA rulemaking. A licensed pharmacy and prescribing provider can confirm current status. Requires a prescription from a licensed provider.
• Acetyl tripeptide-30 citrulline: Regulated as a cosmetic ingredient. Not evaluated or approved as a drug.

Considerations When Comparing Skincare Peptides

Selecting a peptide for a specific skin concern is a clinical and formulation question, not a marketing one. Direct comparison between compounds in different classes is not straightforward — they have been studied in different populations, at different concentrations, using different endpoints, and through different delivery systems.

Your specific skin concern: Signal peptides are relevant if the goal is to support collagen production and address volume loss or fine lines from reduced structural protein. Neurotransmitter-inhibitor peptides are more relevant for expression lines around the eyes and forehead. Carrier peptides are relevant for overall skin repair and antioxidant support. These are different mechanisms addressing different aspects of the same aging process.

Evidence level: Signal peptides (pal-KTTKS) and neurotransmitter-inhibitor peptides (argireline) have the most rigorous human trial data for the class. Newer signal peptide analogs and most enzyme-inhibitor peptides have primarily in vitro evidence. Comfort with the evidence gap matters for expectation-setting.

Formulation quality: Two products listing the same peptide may differ significantly in bioavailability. Ledwoń and colleagues, in a 2021 review in Chemistry & Biodiversity, outlined the stability, delivery, and concentration challenges that separate effective cosmeceutical peptide formulations from ineffective ones. Concentration, vehicle, and pH all affect whether the active compound reaches the dermis intact.

Route: Topical cosmetic application and injectable compounded peptide therapy are not interchangeable. Topical application delivers localized cosmetic-level effects through passive diffusion. Injectable administration delivers systemic concentrations with different pharmacokinetics, mechanisms, and risk profiles. A dermatologist or licensed provider should evaluate injectable peptide approaches separately from topical cosmetic use.

This is not an exhaustive list of considerations. A licensed provider will evaluate the full clinical picture before recommending any injectable peptide compound.

Safety Considerations

Topical cosmetic peptides are generally well-tolerated. Resende and colleagues, in a 2021 review of synthetic peptides in cosmetics for sensitive skin published in Pharmaceuticals (Basel), found a favorable tolerability profile across the major commercial peptide classes. The side effect profile for topical cosmetic peptides does not include the systemic effects associated with injectable peptides or retinoids.

Injectable peptide approaches administered by a licensed provider carry a different safety profile and require clinical evaluation. Side effects vary by compound and individual response. No blanket safety statement applies to the injectable peptide class as a whole. Errante and colleagues' 2021 stability study highlighted that degradation products of peptides may have biological effects not anticipated from the parent compound, adding a formulation quality dimension to safety assessment.

Contraindications that apply broadly to injectable peptide approaches include:

• Pregnancy or breastfeeding — most injectable peptides have not been studied in pregnant or lactating populations; safety has not been established
• Active or history of hormone-sensitive malignancy — compounds that interact with growth factor or copper-mediated signaling pathways carry theoretical concerns about proliferative effects that have not been systematically studied
• Known hypersensitivity to any component of the specific compounded formulation

What to Test Before Starting an Injectable Peptide Approach for Skin

Topical cosmetic peptides do not require laboratory monitoring. Injectable peptide approaches are a different category. Regardless of which injectable compound a provider may discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing expected physiological changes.

• IGF-1: Reflects GH axis activity. Relevant for any injectable peptide that may interact with growth factor pathways. A baseline IGF-1 level establishes where the GH axis stands before any intervention that could influence it.
• Comprehensive metabolic panel (CMP): Covers liver enzymes (ALT, AST), kidney function (creatinine, BUN), and electrolytes. Standard safety baseline for any injectable compound with hepatic or renal clearance.
• CBC (complete blood count): General safety baseline for any injectable therapy.
• hs-CRP: Systemic inflammation marker. High-sensitivity CRP provides baseline inflammatory context relevant to any therapy targeting tissue repair or collagen remodeling.
• Copper serum levels: Relevant specifically for GHK-Cu approaches, where baseline copper status may affect both safety and response.

IGF-1, a comprehensive metabolic panel, CBC, and hs-CRP establish the core baseline before any injectable peptide protocol. These values give a provider the reference points needed to interpret any changes during treatment and establish that organ function is appropriate for an injectable approach.

How to Access Skincare Peptide Approaches Safely

Topical cosmetic peptide products are available over-the-counter. No prescription is required for any of the cosmetic-class ingredients discussed in this article. Selection should be guided by ingredient evidence quality, formulation stability, and realistic expectations about cosmetic-level outcomes.

Injectable peptide therapy is a different matter. Injectable compounded peptides require a prescription from a licensed healthcare provider. A provider evaluation will typically involve reviewing health history, establishing baseline biomarkers, and assessing whether an injectable approach is appropriate for the individual's specific concerns and health status. Access through a licensed provider ensures that dosing is defined, the compound is from a regulated pharmacy, and follow-up monitoring is in place.

Pintea and colleagues, in a 2025 review in Biomolecules, summarized current evidence on peptides being studied for skin senescence, noting that the cosmetic-ingredient literature has decades of formulation experience while injectable peptide compounds have more limited clinical trial data; the review describes compounds as candidates in research contexts, not as established clinical therapies. The gap between what is claimed and what is clinically established is meaningful, and a licensed provider is best positioned to navigate it.

Understanding Your Baseline

With peptide classes spanning topical cosmetics and injectable compounds, baseline data is what makes a clinical conversation productive. For topical cosmetic use, the relevant "baseline" is a dermatologic assessment of skin type, sun damage history, and which anatomical areas concern you most. For injectable peptide approaches, biomarker data transforms the conversation from "which compound is popular" to "which compound addresses what my labs and clinical picture actually show."

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to a topical cosmeceutical approach, an injectable peptide protocol, or a combination, the starting point is the same: objective data about where your biology currently stands.

IMPORTANT NOTICE — Topical Cosmetic Ingredients

The topical peptide ingredients discussed in this article — including palmitoyl pentapeptide (pal-KTTKS/Matrixyl), argireline (acetyl hexapeptide-3), topical GHK-Cu (copper tripeptide-1), acetyl tripeptide-30 citrulline, and related cosmeceutical peptides — are cosmetic ingredients regulated under the FD&C Act as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Cosmetic ingredients are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Claims about physiological effects beyond cosmetic appearance are not supported by FDA evaluation. This content is provided for educational and informational purposes only and does not constitute medical advice.

IMPORTANT SAFETY INFORMATION — Injectable GHK-Cu (Compounded)

GHK-Cu in injectable form is not FDA-approved for any indication. Lawful availability of injectable GHK-Cu through Section 503A compounding depends on the substance's current status on FDA's 503A bulk drug substances list, which is subject to ongoing FDA rulemaking. A licensed pharmacy and prescribing provider can confirm current status. Compounded GHK-Cu is not an FDA-approved product and has not been evaluated by the FDA for safety, efficacy, or manufacturing quality. This page does not constitute medical advice, and this compound should only be accessed through a licensed healthcare provider who can evaluate your eligibility, order baseline labs, and monitor your response. Always consult a qualified healthcare provider before starting any injectable peptide approach.

The safety and efficacy of injectable GHK-Cu for cosmetic or skin-related indications have not been established through adequate and well-controlled clinical trials. Contraindications include pregnancy or breastfeeding (safety not established), history of hormone-sensitive malignancy (theoretical concern, not systematically studied), and known hypersensitivity to any component of the compounded formulation. As of April 2026, injectable GHK-Cu is outside the scope of the February 2026 FDA actions that restricted compounding access to BPC-157 and TB-500; its 503A status is subject to ongoing rulemaking and should be verified with a licensed pharmacy. Full compound reference data available at dailymed.nlm.nih.gov.

Disclaimer: This article discusses topical cosmetic peptide ingredients and, where noted, the injectable form of GHK-Cu. Topical cosmetic peptides are regulated as cosmetic ingredients, not drugs, and are not evaluated or approved to diagnose, treat, cure, or prevent any disease. Injectable GHK-Cu is not FDA-approved and is available through compounding only. This educational content is editorially independent.